Researchers Question Efficacy Of FDA’s Device Surveillance System
Recent medical journal papers call into question the effectiveness of the US agency’s medical device surveillance system, arguing that it’s too slow to pick up on safety signals.
You may also be interested in...
In a new "action plan," FDA is stitching together a plethora of ongoing and proposed initiatives to help spur product safety and quality efforts through increased regulatory authority and more incentives for device-makers.
The US FDA has classified as a Class I recall St Jude Medical's warning to doctors about the higher-than-thought failure rates of its silicone-insulated Riata defibrillator leads.
A group of manufacturers and clinicians is asking the US agency to allow more discussion between manufacturers, labs and clinicians of how genetic factors could influence drug effectiveness – an area known as pharmacogenomics (PGx). The FDA had previously taken several steps to limit these communications.